

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

CD360 (IL-21R) Antibody, anti-human, PE, REAfinity™

RRID:AB_2657745

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-101-477, RRID:AB_2657745

Antibody Information

URL: http://antibodyregistry.org/AB_2657745

Proper Citation: Miltenyi Biotec Cat# 130-101-477, RRID:AB_2657745

Target Antigen: CD360 (IL-21R)

Host Organism: human

Clonality: recombinant monoclonal

Comments: Discontinued: 2023; Applications: MACS Flow Cytometry
Antigen Distribution: B cells, dendritic cells, T cells, NK cells

Antibody Name: CD360 (IL-21R) Antibody, anti-human, PE, REAfinity™

Description: This recombinant monoclonal targets CD360 (IL-21R)

Target Organism: human

Clone ID: Clone REA233

Antibody ID: AB_2657745

Vendor: Miltenyi Biotec

Catalog Number: 130-101-477

Alternative Catalog Numbers: 130-101-476

Record Creation Time: 20231110T034417+0000

Record Last Update: 20260829T041819+0000

Ratings and Alerts

No rating or validation information has been found for CD360 (IL-21R) Antibody, anti-human, PE, REAfinity™.

No alerts have been found for CD360 (IL-21R) Antibody, anti-human, PE, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Rubino V, et al. (2024) IL-21/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy. Cell reports. Medicine, 5(11), 101826.